NCT00280085
Terminated
Not Applicable
Pancreatic Beta-Cell Mass And Function Quantification By Means Of Perfusion Imaging
ConditionsDiabetes Mellitus
DrugsArginine
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diabetes Mellitus
- Sponsor
- Pfizer
- Enrollment
- 29
- Locations
- 1
- Primary Endpoint
- Pancreatic perfusion
- Status
- Terminated
- Last Updated
- 16 years ago
Overview
Brief Summary
Assess pancreatic beta cell function using MR imaging.
Detailed Description
The study was terminated on July 31st, 2007. The study was discontinued, as we have not met the primary end point, differentiation between normal volunteers and subjects with type 1 diabetes mellitus. There were no safety concerns.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Normal Volunteers
- •T1DM and T2DM subjects
Exclusion Criteria
- •Concomitant severe conditions
Outcomes
Primary Outcomes
Pancreatic perfusion
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Assessment of Beta Cell Mass by PET Scans With [11C] Dihydrotetrabenazine (DTBZ) in Longstanding Type 1 Diabetes.Type 1 DiabetesNCT00738907National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)18
Completed
Not Applicable
PET Scan Imaging of Beta Cell MassType 1 DiabetesObesityNCT00771576Columbia University30
Completed
Not Applicable
Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic PatientsDiabetes Mellitus, Type 1NCT00958997Yale University16
Recruiting
Not Applicable
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes MellitusNCT05662189Azienda Ospedaliero-Universitaria di Parma70
Completed
Not Applicable
Immune Biomarkers of Residual Beta-cell Mass in Type 1 DiabetesType 1 DiabetesNCT01747967Assistance Publique - Hôpitaux de Paris156